RBM17P2

Across TCGA pan-cancer cohorts, RBM17P2 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RBM17P2’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RBM17P2 RNA is repressed in tumor relative to normal tissue. In most cancer types RBM17P2 is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.

BRCA and LUSC are the cancer types where RBM17P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RBM17P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	III,IV	−0.032	.003	2	view →
LUSC	Male	II,III,IV	−0.013	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

RBM17P2–BRCA

Open the BRCA breakdown →